Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
6(60%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
10%
Ph phase_1
8
80%
Ph phase_2
1
10%

Phase Distribution

8

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
8(80.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

10

all time

Status Distribution
Active(7)
Completed(1)
Other(2)

Detailed Status

Recruiting5
unknown2
Active, not recruiting1
Not yet recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (80.0%)
Phase 21 (10.0%)
Phase 31 (10.0%)

Trials by Status

unknown220%
active_not_recruiting110%
not_yet_recruiting110%
completed110%
recruiting550%

Recent Activity

6 active trials
Showing 5 of 10
recruitingphase_1

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )

NCT07053670
recruitingphase_3

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

NCT07103668
recruitingphase_1

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

NCT02917083
active_not_recruitingphase_1

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

NCT04577326
not_yet_recruitingphase_1

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )

NCT07032324
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07053670Phase 1

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )

Recruiting
NCT07103668Phase 3

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Recruiting
NCT02917083Phase 1

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Recruiting
NCT04577326Phase 1

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Active Not Recruiting
NCT07032324Phase 1

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )

Not Yet Recruiting
NCT06822868Phase 1

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Recruiting
NCT06734871Phase 1

A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma

Recruiting
NCT05089266Phase 1

Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors

Unknown
NCT03068416Phase 2

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

Completed
NCT03271632Phase 1

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10